{"gene":"MSH2","run_date":"2026-06-10T02:59:51","timeline":{"discoveries":[{"year":1993,"finding":"Human MSH2 (hMSH2) is a homolog of bacterial MutS and yeast MSH proteins. Expression of hMSH2 in E. coli causes a dominant mutator phenotype, consistent with interference with the normal bacterial mismatch repair pathway, establishing MSH2 as a mismatch repair factor.","method":"Heterologous expression in E. coli with mutator phenotype readout; gene mapping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional expression assay in bacteria replicated in subsequent studies; foundational paper establishing the basic function","pmids":["8252616"],"is_preprint":false},{"year":1994,"finding":"Yeast MSH2, MLH1, and PMS1 form a ternary complex during mismatch repair initiation: MLH1 and PMS1 physically associate as a heterodimer and together bind an MSH2-heteroduplex complex containing a G-T mismatch.","method":"Physical interaction/co-binding assay; in vitro ternary complex formation with G-T mismatch-containing heteroduplex DNA","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of ternary complex, replicated by subsequent biochemical studies","pmids":["8066446"],"is_preprint":false},{"year":1996,"finding":"S. cerevisiae MSH2 operates via two mismatch repair pathways: one recognizing single-base mispairs requiring MSH2-MSH6, and a second recognizing insertion/deletion mispairs requiring MSH2-MSH3 or MSH2-MSH6. MSH2 physically interacts with both MSH3 and MSH6 to form distinct heterodimers.","method":"Mutation rate measurement across msh2/msh3/msh6 combinations; physical interaction studies between MSH2 and MSH3/MSH6","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis combined with physical interaction studies, replicated across multiple studies","pmids":["8600025"],"is_preprint":false},{"year":1997,"finding":"Human MSH2 protein binds to slipped-strand DNA structures (S-DNA and SI-DNA) formed from trinucleotide repeat sequences (CTG/CAG) in a structure-specific and length-dependent manner, with preferential binding to looped-out CAG repeat sequences.","method":"Band-shift (EMSA) assay with purified MSH2 protein and synthetic slipped-strand DNA substrates","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro binding assay with purified protein, single lab, single method","pmids":["9215683"],"is_preprint":false},{"year":1997,"finding":"The yeast MLH1-PMS1 heterodimer, by itself showing no affinity for mismatched DNA, greatly enhances the mismatch binding ability of MSH2-MSH3 upon interaction.","method":"Purification of MLH1-PMS1 heterodimer; gel mobility shift assay for mismatch DNA binding enhancement","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins, biochemical binding assay, single lab but orthogonal readouts","pmids":["9368761"],"is_preprint":false},{"year":1999,"finding":"Msh2 is required for in vivo DNA damage-induced apoptosis in the intestinal epithelium in response to methylating agents (temozolomide, MNNG, cisplatin). This apoptotic response is primarily mediated through a p53-dependent pathway, with a secondary p53-independent delayed death also requiring Msh2.","method":"Msh2 null mouse model; in vivo apoptosis assay after genotoxic treatment; double-mutant analysis with p53","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse model with defined phenotypic readout, epistasis with p53, replicated in subsequent studies","pmids":["10097137"],"is_preprint":false},{"year":2000,"finding":"MSH3 and MSH6, but not MSH2, contain N-terminal PCNA-interacting motifs. MSH2-MSH6 complex binds PCNA through MSH6's motif; alanine substitutions in the PCNA-binding motif of Msh6 or Msh3 elevated mutation rates. MSH3/MSH6 interaction with PCNA facilitates early steps in mismatch repair.","method":"Peptide binding to PCNA; alanine-substitution mutagenesis; mutation rate assay in yeast; mismatch repair inhibition assay in human cell extract","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with functional readout, peptide binding assay, in vitro repair inhibition assay; multiple orthogonal methods","pmids":["11005803"],"is_preprint":false},{"year":2002,"finding":"MSH2-MSH6 (MutSα) forms a stable ternary complex with PCNA on homoduplex DNA, but MSH2-MSH6 binding to a heteroduplex (G/T mismatch) disrupts its interaction with PCNA. ATP addition restores PCNA binding, supporting a model where MSH2-MSH6 is transferred from PCNA to mispaired bases.","method":"Gel filtration and pull-down assays; ternary complex formation with PCNA, MSH2-MSH6, and homoduplex or heteroduplex DNA; ATP addition experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins, multiple conditions tested, mechanistic model supported by biochemical data","pmids":["12435741"],"is_preprint":false},{"year":2002,"finding":"MSH2 and MSH6 are phosphorylated in vitro by protein kinase C and casein kinase II (but not PKA), and are phosphorylated in vivo. Phosphorylation of MSH2 and MSH6 increases mismatch-binding activity of MutSα and is required for methylation-induced nuclear translocation of the MutSα repair complex.","method":"In vitro kinase assays; phosphatase treatment and kinase inhibitor experiments in cells; mismatch-binding assay; subcellular localization by fractionation","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo phosphorylation with functional consequence (binding and translocation), multiple methods, single lab","pmids":["11972333"],"is_preprint":false},{"year":2002,"finding":"MSH2 and p53 co-localize in discrete nuclear foci during S phase, associate with recombination factors Rad50 and Rad51, and coexist in the same nuclear DNA-protein complexes during S phase, suggesting MSH2 plays a role in homologous recombination surveillance during DNA replication.","method":"Immunofluorescence colocalization; nuclear fractionation with co-immunoprecipitation; cell synchronization","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and colocalization, multiple methods, single lab","pmids":["12101417"],"is_preprint":false},{"year":2003,"finding":"MSH2 interacts with the ATR kinase to form a signaling module that regulates phosphorylation of Chk1 and SMC1 in response to the DNA methylating agent MNNG. MSH2 and Rad17 are required for S-phase checkpoint activation to suppress DNA synthesis after MNNG treatment.","method":"Co-immunoprecipitation of endogenous MSH2 and ATR; siRNA knockdown; checkpoint assays; Chk1 and SMC1 phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional epistasis (knockdown and checkpoint assay), multiple orthogonal methods in single lab","pmids":["14657349"],"is_preprint":false},{"year":2004,"finding":"The DNA mismatch repair and DNA damage-induced apoptosis functions of Msh2 can be uncoupled: the G674A missense mutation in the conserved ATPase domain abrogates mismatch repair but retains DNA damage signaling for apoptosis. Msh2-mediated apoptosis is an independent tumor suppressor function.","method":"Knock-in mouse model (Msh2-G674A); tumor formation assay; chemotherapy response assay; apoptosis measurement","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knock-in mouse with separation-of-function mutation, phenotypic readout across multiple cancer and drug-response endpoints; replicated in biochemical studies","pmids":["14744764"],"is_preprint":false},{"year":2004,"finding":"ERCC1 physically interacts with MSH2 complexes in HeLa cell extracts. The minimum region in ERCC1 required for co-immunoprecipitation of MSH2 is the carboxyl-terminal domain (aa 184-260), overlapping with the XPF-binding domain. This interaction is involved cooperatively in resistance to cisplatin (CDDP) in mammalian cells; MSH2 deficiency suppresses ERCC1-dependent CDDP resistance in XPA-deficient cells.","method":"Co-immunoprecipitation from HeLa cell extracts; tagged ERCC1 in COS7 cells; siRNA knockdown; double mutant cell analysis (Xpa/Msh2 null cells)","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus genetic epistasis in null cells, single lab, multiple methods","pmids":["14706347"],"is_preprint":false},{"year":2005,"finding":"Human MSH2-MSH3 binds to CAG-hairpin DNA (an expansion intermediate); this binding inhibits the ATPase activity of MSH2-MSH3 and alters both ADP/ATP affinity and protein-DNA binding interfaces. Inhibition depends on A.A mispairs in the hairpin stem and the hairpin structure itself. This functional defect is proposed to misdirect repair and promote expansion.","method":"In vitro binding assay with purified MSH2-MSH3 and synthetic CAG-hairpin DNA; ATPase assay; nucleotide binding assay; mutagenesis of hairpin substrate","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — purified protein with synthetic substrates, multiple biochemical assays (binding, ATPase, nucleotide affinity), single lab","pmids":["16025128"],"is_preprint":false},{"year":2006,"finding":"The MSH2 DNA-binding domain I (msh2Δ1 deletion) shows a separation-of-function phenotype: it is dispensable for MSH2-MSH6-mediated MMR but is required for MSH2-MSH3-mediated MMR. Domain I of MSH2 contributes a non-specific DNA binding activity, while domain I of MSH3 contributes mismatch binding specificity.","method":"Yeast genetic assays (mutation rate); purified Msh2-Msh3 mispair binding analysis; domain deletion mutants","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding with purified proteins plus genetic readout, multiple complementary methods, single lab","pmids":["17157869"],"is_preprint":false},{"year":2007,"finding":"Msh2-Msh3 exhibits robust binding to specific base-base mispairs (not only insertion/deletion loops), consistent with a role in repair of base-base mismatches and suppression of homology-mediated duplication/deletion mutations; this parallels Mlh1-Mlh3 mutant phenotypes.","method":"Yeast genetic assays (mutation rate, mutation spectrum at CAN1); purified Msh2-Msh3 mispair binding assay with DNA substrates derived from CAN1","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding with purified protein plus genetic assays, orthogonal methods, single lab","pmids":["17636021"],"is_preprint":false},{"year":2009,"finding":"MSH2-MSH3 recognizes small DNA loops via a mechanism distinct from MSH2-MSH6. Upon loop binding, MSH2-MSH3 adopts a specific nucleotide signature (ADP in MSH2, empty MSH3 subunit). ATP binding and hydrolysis in MSH3 promotes ADP-ATP exchange in MSH2, generating a hydrolysis-independent ATP-MSH2-MSH3-ADP intermediate specific to loop-bound complex.","method":"Nucleotide binding assays with purified human MSH2-MSH3; ATPase assays; fluorescence-based nucleotide occupancy measurements on defined DNA substrates","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assays with purified protein, multiple nucleotide binding methods, mechanistic detail established in single rigorous study","pmids":["19377479"],"is_preprint":false},{"year":2009,"finding":"The MSH2 ATPase domain G674A mutation strongly reduces CTG repeat expansion and leads instead to contractions in DM1 transgenic mice (mimicking Msh2-null or Msh3-null deficiency), establishing that trinucleotide repeat expansion requires a functional MSH2 ATPase domain.","method":"Transgenic mouse cross; repeat instability analysis; protein level measurement","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean mouse genetic experiment with separation-of-function allele, quantitative repeat instability readout, single lab","pmids":["19436705"],"is_preprint":false},{"year":2009,"finding":"MSH2 conformational change upon DNA binding is allosterically coupled to ATPase domain activity: in the absence of DNA, the clamp and lever domains of MSH6 and MSH2 open asymmetrically, and this opening is coupled to changes in the ATPase domains that diminish ATPase activity.","method":"Molecular dynamics simulation of human MSH2-MSH6 based on crystal structure; analysis of domain movements and ATPase domain changes","journal":"Biophysical journal","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational simulation only, no experimental validation in this paper","pmids":["19486659"],"is_preprint":false},{"year":2009,"finding":"MSH2 deficiency in telomerase-deficient mice abolishes p21/p53-dependent cell-cycle arrest in response to short telomeres, eliminating the tumor suppressor activity of short telomeres and preventing degenerative pathologies by rescuing proliferative defects.","method":"Double knockout mice (MSH2(-/-) Terc(-/-)); tumor analysis; proliferation assay; p21/p53 pathway analysis","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — double KO mouse model with defined phenotypic readouts, single lab","pmids":["18986375"],"is_preprint":false},{"year":2012,"finding":"Human MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D) mutant proteins both fail to support mismatch repair in vitro while retaining mismatch recognition activity. MSH2(G674A)-MSH6 has a partial defect in nucleotide binding, while MSH2-MSH6(T1219D) fails to couple nucleotide binding and mismatch recognition. Both mutants remain bound at the mismatch and fail to promote excision, inhibiting MMR in a dominant manner.","method":"In vitro mismatch repair assay; kinetic DNA binding assays; ATPase activity measurement; excision step analysis with purified mutant proteins","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified mutant proteins, multiple biochemical assays, mechanistic separation of defects established","pmids":["22277660"],"is_preprint":false},{"year":2014,"finding":"HDAC6 sequentially deacetylates and ubiquitinates MSH2, leading to its proteasomal degradation. HDAC6 reduces cellular MSH2 levels, decreases mismatch repair activity, and reduces cellular sensitivity to DNA-damaging agents.","method":"Co-immunoprecipitation; ubiquitination assay; HDAC6 depletion/overexpression; mismatch repair activity assay; cell sensitivity assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional ubiquitination assays plus cellular readouts (MMR activity, drug sensitivity), multiple methods, single lab","pmids":["24882211"],"is_preprint":false},{"year":2014,"finding":"Yeast Mlh1-Mlh3 is a metal-dependent endonuclease that is stimulated by Msh2-Msh3 to make single-strand breaks in supercoiled DNA, supporting a direct role for this endonuclease activity in resolving recombination intermediates and in mismatch repair.","method":"Purification of Mlh1-Mlh3; in vitro endonuclease assay; stimulation by purified Msh2-Msh3","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins, direct enzymatic activity assay, single lab","pmids":["24403070"],"is_preprint":false},{"year":2014,"finding":"PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair. PCNA mutations disrupting Msh2-Msh6 binding or Mlh1-Pms1 endonuclease activation impair Exo1-independent MMR; Msh2-Msh6 localizes PCNA to repair sites after mispair recognition to activate the endonuclease.","method":"Genetic screen for PCNA mutants; mismatch repair assays; Mlh1-Pms1 focus accumulation assay; epistasis with msh6 PCNA-binding mutants","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic screen with multiple alleles plus epistasis plus cell biological assay (foci), replicated through multiple experimental approaches","pmids":["24981171"],"is_preprint":false},{"year":2014,"finding":"Depletion of MSH2 suppresses aberrant DNA damage response and ICL sensitivity in cells lacking FANCJ-MLH1 interaction, BRCA1, or FANCD2, demonstrating that MSH2-dependent DNA damage signaling underlies synthetic lethality in BRCA-FA pathway-deficient cells. Rescue is through a Rad18-dependent mechanism.","method":"siRNA depletion of MSH2; cell viability and ICL sensitivity assays; cell cycle analysis; Msh2 null mouse cells (Fancd2-null primary cells); epistasis with Rad18","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in multiple cell backgrounds plus mouse cell validation, single lab","pmids":["24966277"],"is_preprint":false},{"year":2016,"finding":"MSH2-MSH3 acts as a component of the BER machinery to promote trinucleotide repeat expansion: MSH2-MSH3 stimulates DNA polymerase β (pol β) to copy through TNRs and enhances formation of the flap precursor for expansion, converting the outcome of TNR instability from deletion to expansion during oxidized base removal.","method":"In vitro BER reconstitution assay with purified MSH2-MSH3 and pol β; flap formation assay; deletion/expansion measurement with defined DNA substrates","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins and defined substrates, multiple functional assays, single lab","pmids":["27546332"],"is_preprint":false},{"year":2018,"finding":"The C-terminal unstructured domain of yeast Exo1 contains two Msh2-interacting peptide (SHIP) boxes that interact with Msh2 to recruit Exo1 to repair sites. The msh2-M470I mutation eliminates SHIP-Msh2 interactions. Wild-type but not mutant SHIP peptides block Exo1-dependent MMR in vitro, establishing that Msh2 has a peptide-binding interface for Exo1 tethering.","method":"Yeast genetics; in vitro mismatch repair assay; SHIP peptide competition; mutagenesis (msh2-M470I); identification of new SHIP-box proteins","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution plus mutagenesis and genetic validation, multiple orthogonal methods, single lab","pmids":["30061603"],"is_preprint":false},{"year":2013,"finding":"MSH2 physically interacts with DNA polymerase kappa (Polκ). MSH2 depletion impairs PCNA monoubiquitination and the formation of UV-induced Polκ and other TLS polymerase foci. MSH2 can also regulate post-UV TLS polymerase focus formation in a PCNA monoubiquitination-independent fashion (in Rad18-deficient cells), facilitating translesion synthesis across CPD photoproducts.","method":"Co-immunoprecipitation combined with mass spectrometry; siRNA knockdown; focus formation assay after UV; TLS assay in living cells","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS identification plus functional readouts (focus formation, TLS), single lab, multiple methods","pmids":["24038355"],"is_preprint":false},{"year":2021,"finding":"OTUB1 (an OTU family deubiquitinase) inhibits MSH2 ubiquitination by blocking E2 ligase ubiquitin transfer activity. Depleting OTUB1 promotes ubiquitination and proteasomal degradation of MSH2, increases mutation frequency, and causes resistance to MNNG and cisplatin.","method":"Functional ubiquitination and deubiquitination assays; OTUB1 depletion in cells; mutation frequency assay; drug sensitivity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional ubiquitination assay plus cellular readouts (mutation rate, drug sensitivity), multiple methods, mechanistic model established, single lab","pmids":["33640455"],"is_preprint":false},{"year":2003,"finding":"MAX, the heterodimeric partner of c-MYC, physically interacts with MSH2 both in vitro (GST pull-down) and in vivo (co-immunoprecipitation from tumor cell extracts), identifying MAX as a binding partner of MSH2.","method":"Yeast two-hybrid; GST-fusion pull-down; co-immunoprecipitation from human tumor cell extracts","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus in vitro pull-down, replicated in two experimental systems, single lab","pmids":["12584560"],"is_preprint":false},{"year":2022,"finding":"MSH2 exerts a non-canonical epigenomic function in gastric cancer independent of its DNA repair catalytic activity: it binds tumor-associated super-enhancers controlling cell adhesion gene expression, enables chromatin rewiring and enhancer-promoter interactions, and maintains histone acetylation. This requires MSH6 and the SWI/SNF remodeler SMARCA4/BRG1. Loss of MSH2 causes deficient cell adhesion and synthetic lethality to BET inhibition.","method":"CRISPR-based mass spectrometry; genome-wide CRISPR functional screening; ChIP-seq; Hi-C (enhancer-promoter interaction); histone modification analysis; rescue experiments with catalytic-dead MSH2; in vitro and in vivo tumorigenesis assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genomic and functional methods (CRISPR screen, ChIP, Hi-C, rescue with catalytic-dead mutant), multiple readouts establishing mechanistic independence from repair activity","pmids":["35583999"],"is_preprint":false},{"year":2006,"finding":"Msh2 deficiency in primary mouse embryonic fibroblasts leads to chromosome aneuploidy, centrosome amplification, defective mitotic spindle organization, unequal chromosome segregation, and increased chromosome end-to-end fusions (telomere capping defects), without changes in telomerase activity, telomere length, or telomere recombination.","method":"Msh2(-/-) MEFs; cytogenetic analysis; centrosome immunofluorescence; telomere FISH; telomerase activity assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO cells with multiple cytological readouts (cytogenetics, centrosome, telomere), single lab","pmids":["16331258"],"is_preprint":false}],"current_model":"MSH2 is an obligate subunit of the MutSα (MSH2-MSH6) and MutSβ (MSH2-MSH3) heterodimers that initiate eukaryotic DNA mismatch repair by recognizing base-base mismatches and insertion/deletion loops, respectively; upon mismatch binding, MSH2-MSH6 undergoes ATP-driven conformational changes that release it from PCNA (which loads the complex onto newly replicated DNA) and enable recruitment of the MLH1-PMS1/PMS2 endonuclease and Exo1 via direct MSH2-SHIP-box interactions; MSH2 also functions as a damage-signaling platform that interacts with ATR to phosphorylate Chk1 and SMC1 and trigger apoptosis independently of repair; MSH2-MSH3 additionally promotes trinucleotide repeat expansion by inhibiting ATPase activity when bound to CAG hairpins and by stimulating pol β during base excision repair; MSH2 protein stability is regulated by HDAC6-mediated deacetylation/ubiquitination (promoting degradation) and OTUB1-mediated deubiquitination (stabilization); and MSH2 has a non-canonical epigenomic role in which it binds super-enhancers via SMARCA4/BRG1 to maintain chromatin architecture at cell adhesion genes, independent of its catalytic repair activity."},"narrative":{"mechanistic_narrative":"MSH2 is the obligate, shared subunit of the eukaryotic mismatch-recognition heterodimers that initiate DNA mismatch repair (MMR): a MutS homolog whose heterologous expression confers a dominant mutator phenotype [PMID:8252616], it partners with MSH6 to recognize base-base mispairs and with MSH3 to recognize insertion/deletion loops [PMID:8600025], and these complexes nucleate a ternary repair assembly with the MLH1-PMS1 heterodimer at heteroduplex DNA [PMID:8066446, PMID:9368761]. Loading is coordinated with replication through PCNA, which forms a stable ternary complex with MutSα on homoduplex DNA; mismatch binding disrupts the PCNA interaction and ATP restores it, supporting transfer of MutSα from PCNA onto the mispair [PMID:12435741], after which PCNA and MutSα activate the latent MLH1-PMS1 endonuclease and license Exo1-dependent or Exo1-independent excision [PMID:24981171]; Exo1 is recruited directly through SHIP-box peptides that dock on an MSH2 interface disrupted by the msh2-M470I mutation [PMID:30061603]. ATP-driven conformational cycling within the MSH2-MSH6 ATPase domains couples nucleotide binding to mismatch recognition and downstream excision, as defined by separation-of-function mutants (G674A and the MSH6 T1219D coupling mutant) that retain mismatch binding but fail to support repair [PMID:22277660]. Beyond repair, MSH2 is a damage-signaling platform: it associates with ATR to drive Chk1 and SMC1 phosphorylation and S-phase checkpoint activation after methylation damage [PMID:14657349] and is required for genotoxin-induced, largely p53-dependent apoptosis [PMID:10097137]; this signaling function is genetically separable from repair, since the G674A ATPase mutant abolishes MMR yet preserves apoptotic tumor suppression [PMID:14744764]. MSH2-MSH3 also promotes trinucleotide repeat expansion, binding CAG hairpins to inhibit its own ATPase [PMID:16025128] and stimulating DNA polymerase β during base excision repair to convert repeat instability toward expansion [PMID:27546332], a process requiring a functional MSH2 ATPase domain in vivo [PMID:19436705]. MSH2 abundance is set by opposing enzymes—HDAC6-mediated deacetylation/ubiquitination promoting degradation [PMID:24882211] and OTUB1-mediated protection from ubiquitination [PMID:33640455]. Independent of catalytic repair, MSH2 carries a non-canonical epigenomic role, binding super-enhancers via MSH6 and SMARCA4/BRG1 to maintain chromatin architecture and cell adhesion gene expression [PMID:35583999].","teleology":[{"year":1993,"claim":"Established MSH2 as the human counterpart of bacterial MutS and a bona fide mismatch repair factor, defining the gene's foundational function.","evidence":"Heterologous expression of hMSH2 in E. coli producing a dominant mutator phenotype, with gene mapping","pmids":["8252616"],"confidence":"High","gaps":["Did not define which mammalian partners MSH2 uses","No direct demonstration of mismatch binding by the human protein in this study"]},{"year":1996,"claim":"Resolved that MSH2 is a shared subunit forming two distinct heterodimers with division of substrate labor, explaining how a single protein covers both base-base and indel mispairs.","evidence":"Yeast mutation-rate epistasis across msh2/msh3/msh6 combinations plus MSH2-MSH3/MSH6 physical interaction assays","pmids":["8600025"],"confidence":"High","gaps":["Did not establish the structural basis of differential substrate recognition","Human reconstitution not shown here"]},{"year":1997,"claim":"Connected mismatch recognition to downstream MutL recruitment by showing MSH2-heteroduplex complexes form a ternary assembly with MLH1-PMS1 and that MLH1-PMS1 enhances MSH2-MSH3 mismatch binding.","evidence":"In vitro ternary complex formation on G-T heteroduplex DNA and gel-shift binding enhancement with purified MLH1-PMS1","pmids":["8066446","9368761"],"confidence":"High","gaps":["Order of events relative to replication not addressed","Endonuclease activation step not yet defined"]},{"year":1997,"claim":"Provided a biochemical basis for MSH2 involvement in trinucleotide repeat instability by showing structure-specific binding to slipped-strand repeat DNA.","evidence":"EMSA with purified MSH2 on synthetic CTG/CAG slipped-strand substrates","pmids":["9215683"],"confidence":"Medium","gaps":["Single lab, single method (EMSA)","Functional consequence for expansion not tested here","MSH2-MSH3 vs MSH2 alone not resolved"]},{"year":2002,"claim":"Defined the PCNA hand-off mechanism that times MutSα loading to replication, showing mismatch binding releases PCNA and ATP restores it.","evidence":"Gel filtration and pull-down ternary complex assays comparing homoduplex versus G/T heteroduplex with ATP addition","pmids":["12435741"],"confidence":"High","gaps":["Did not show how released PCNA later activates the endonuclease","In vivo timing not established"]},{"year":2002,"claim":"Linked MSH2 to broader S-phase genome surveillance by placing it in S-phase nuclear foci with p53 and recombination factors.","evidence":"Immunofluorescence colocalization and nuclear co-immunoprecipitation in synchronized cells","pmids":["12101417"],"confidence":"Medium","gaps":["Correlative localization without direct functional dissection","Whether MSH2 acts in homologous recombination not mechanistically shown"]},{"year":2003,"claim":"Identified MSH2 as a direct damage-signaling platform for the ATR-Chk1 axis, separating signaling from repair catalysis.","evidence":"Endogenous MSH2-ATR co-IP, siRNA knockdown, and Chk1/SMC1 phosphorylation and S-phase checkpoint assays after MNNG","pmids":["14657349"],"confidence":"High","gaps":["Direct kinase-substrate scaffolding mechanism not resolved","Stoichiometry and dynamics of the MSH2-ATR module unknown"]},{"year":2004,"claim":"Genetically uncoupled MSH2's apoptotic/damage-signaling tumor suppressor role from its repair function using a separation-of-function ATPase mutant.","evidence":"Msh2-G674A knock-in mouse with tumor, chemotherapy-response, and apoptosis readouts","pmids":["14744764"],"confidence":"High","gaps":["Molecular reason the ATPase mutant retains signaling not defined","Did not identify the signaling effector distinct from repair"]},{"year":2012,"claim":"Provided the biochemical mechanism for the repair/signaling split, showing ATPase and nucleotide-coupling mutants retain mismatch binding but stall before excision and act dominantly.","evidence":"In vitro MMR, kinetic DNA binding, ATPase, and excision assays with purified MSH2(G674A) and MSH6(T1219D) proteins","pmids":["22277660"],"confidence":"High","gaps":["Did not test apoptotic signaling output of these mutants biochemically","Structural snapshot of the stalled intermediate not provided"]},{"year":2014,"claim":"Completed the catalytic logic of initiation by showing PCNA plus MutSα activate the MLH1-PMS1 endonuclease for Exo1-independent repair.","evidence":"Yeast PCNA mutant screen with MMR assays, Mlh1-Pms1 focus accumulation, and epistasis with msh6 PCNA-binding mutants","pmids":["24981171"],"confidence":"High","gaps":["Mechanism of nick placement directionality not fully defined","Human reconstitution not shown in this study"]},{"year":2018,"claim":"Defined the direct molecular interface by which MSH2 tethers the nuclease Exo1 via SHIP-box peptides.","evidence":"Yeast genetics, in vitro MMR with SHIP peptide competition, and msh2-M470I interface mutagenesis","pmids":["30061603"],"confidence":"High","gaps":["Atomic structure of the SHIP-MSH2 interface not solved here","Generality across other SHIP-box proteins only partially explored"]},{"year":2016,"claim":"Mechanistically explained how MSH2-MSH3 drives repeat expansion by acting within base excision repair to stimulate pol β and bias outcomes toward expansion.","evidence":"In vitro BER reconstitution with purified MSH2-MSH3 and pol β, flap-formation and deletion/expansion assays on defined substrates","pmids":["27546332","16025128","19436705"],"confidence":"High","gaps":["In vivo coordination between BER and MMR pathways at repeats not resolved","Tissue-specific determinants of expansion not addressed"]},{"year":2021,"claim":"Established that MSH2 protein levels, and thereby repair capacity and drug response, are set by opposing ubiquitin-pathway enzymes.","evidence":"HDAC6 deacetylation/ubiquitination and OTUB1 deubiquitination assays with cellular MMR activity, mutation frequency, and MNNG/cisplatin sensitivity readouts","pmids":["24882211","33640455"],"confidence":"High","gaps":["E3 ligase responsible for MSH2 ubiquitination not pinpointed","Crosstalk between acetylation and ubiquitination signals not fully mapped"]},{"year":2022,"claim":"Revealed a repair-independent epigenomic function in which MSH2 maintains super-enhancer chromatin architecture and cell adhesion gene expression.","evidence":"CRISPR-MS, genome-wide CRISPR screen, ChIP-seq, Hi-C, and rescue with catalytic-dead MSH2 in gastric cancer models","pmids":["35583999"],"confidence":"High","gaps":["How MSH2 is targeted to specific super-enhancers not fully defined","Whether this role exists outside gastric cancer not established"]},{"year":null,"claim":"How MSH2's repair, ATR-dependent signaling, repeat-expansion, and chromatin functions are partitioned and regulated within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking ATPase conformational states to the choice between repair, signaling, and chromatin roles","The E3 ligase and full regulatory network controlling MSH2 stability are incomplete","The recruitment determinants directing MSH2 to super-enhancers versus mismatches are unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,13,14,15,16]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[7,13,16,20]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[13,16,20]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[5,10,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[23,26]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,9,10]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[30]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,1,2,7,23,26]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[5,10,11]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,11]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,17,25]}],"complexes":["MutSα (MSH2-MSH6)","MutSβ (MSH2-MSH3)"],"partners":["MSH6","MSH3","MLH1","PMS1","PCNA","EXO1","ATR","SMARCA4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P43246","full_name":"DNA mismatch repair protein Msh2","aliases":["MutS protein homolog 2"],"length_aa":934,"mass_kda":104.7,"function":"Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Recruits DNA helicase MCM9 to chromatin which unwinds the mismatch containing DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P43246/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MSH2","classification":"Not Classified","n_dependent_lines":23,"n_total_lines":1208,"dependency_fraction":0.01903973509933775},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"MSH6","stoichiometry":10.0},{"gene":"ARFGEF1","stoichiometry":0.2},{"gene":"CANX","stoichiometry":0.2},{"gene":"CBX1","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/MSH2","total_profiled":1310},"omim":[{"mim_id":"619096","title":"MISMATCH REPAIR CANCER SYNDROME 2; MMRCS2","url":"https://www.omim.org/entry/619096"},{"mim_id":"615823","title":"SLX1 HOMOLOG B, STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT; SLX1B","url":"https://www.omim.org/entry/615823"},{"mim_id":"615822","title":"SLX1 HOMOLOG A, STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT; SLX1A","url":"https://www.omim.org/entry/615822"},{"mim_id":"615083","title":"COLORECTAL CANCER, SUSCEPTIBILITY TO, 12; CRCS12","url":"https://www.omim.org/entry/615083"},{"mim_id":"614350","title":"LYNCH SYNDROME 5; LYNCH5","url":"https://www.omim.org/entry/614350"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MSH2"},"hgnc":{"alias_symbol":["HNPCC","HNPCC1","MSH-2"],"prev_symbol":["COCA1"]},"alphafold":{"accession":"P43246","domains":[{"cath_id":"3.40.1170.10","chopping":"12-123","consensus_level":"high","plddt":81.7512,"start":12,"end":123},{"cath_id":"3.30.420.110","chopping":"145-296","consensus_level":"high","plddt":84.6368,"start":145,"end":296},{"cath_id":"1.10.1420.10","chopping":"331-614","consensus_level":"medium","plddt":90.3498,"start":331,"end":614},{"cath_id":"3.40.50.300","chopping":"624-824","consensus_level":"high","plddt":87.9857,"start":624,"end":824},{"cath_id":"1.20.1270","chopping":"867-934","consensus_level":"medium","plddt":73.3003,"start":867,"end":934}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43246","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43246-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43246-F1-predicted_aligned_error_v6.png","plddt_mean":85.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MSH2","jax_strain_url":"https://www.jax.org/strain/search?query=MSH2"},"sequence":{"accession":"P43246","fasta_url":"https://rest.uniprot.org/uniprotkb/P43246.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43246/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43246"}},"corpus_meta":[{"pmid":"8252616","id":"PMC_8252616","title":"The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8252616","citation_count":2514,"is_preprint":false},{"pmid":"21642682","id":"PMC_21642682","title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.","date":"2011","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/21642682","citation_count":843,"is_preprint":false},{"pmid":"8600025","id":"PMC_8600025","title":"Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair.","date":"1996","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8600025","citation_count":503,"is_preprint":false},{"pmid":"25036629","id":"PMC_25036629","title":"Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25036629","citation_count":381,"is_preprint":false},{"pmid":"7550317","id":"PMC_7550317","title":"MSH2 deficient mice are viable and susceptible to lymphoid tumours.","date":"1995","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7550317","citation_count":355,"is_preprint":false},{"pmid":"8066446","id":"PMC_8066446","title":"MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8066446","citation_count":292,"is_preprint":false},{"pmid":"7713503","id":"PMC_7713503","title":"Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7713503","citation_count":259,"is_preprint":false},{"pmid":"1982429","id":"PMC_1982429","title":"A new homeobox-containing gene, msh-2, is transiently expressed early during mesoderm formation of Drosophila.","date":"1990","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1982429","citation_count":222,"is_preprint":false},{"pmid":"23255516","id":"PMC_23255516","title":"Cancer risks for MLH1 and MSH2 mutation carriers.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/23255516","citation_count":196,"is_preprint":false},{"pmid":"16025128","id":"PMC_16025128","title":"(CAG)(n)-hairpin DNA binds to Msh2-Msh3 and changes properties of mismatch recognition.","date":"2005","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16025128","citation_count":189,"is_preprint":false},{"pmid":"11005803","id":"PMC_11005803","title":"Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 and MSH2-MSH3 complexes.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11005803","citation_count":182,"is_preprint":false},{"pmid":"14744764","id":"PMC_14744764","title":"An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14744764","citation_count":155,"is_preprint":false},{"pmid":"10097137","id":"PMC_10097137","title":"Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10097137","citation_count":152,"is_preprint":false},{"pmid":"14657349","id":"PMC_14657349","title":"MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14657349","citation_count":144,"is_preprint":false},{"pmid":"17003395","id":"PMC_17003395","title":"Prediction of MLH1 and MSH2 mutations in Lynch syndrome.","date":"2006","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/17003395","citation_count":137,"is_preprint":false},{"pmid":"28790115","id":"PMC_28790115","title":"MSH2 Loss in Primary Prostate Cancer.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28790115","citation_count":133,"is_preprint":false},{"pmid":"9215683","id":"PMC_9215683","title":"Human MSH2 binds to trinucleotide repeat DNA structures associated with neurodegenerative diseases.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9215683","citation_count":126,"is_preprint":false},{"pmid":"24882211","id":"PMC_24882211","title":"HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24882211","citation_count":121,"is_preprint":false},{"pmid":"23391514","id":"PMC_23391514","title":"Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities.","date":"2013","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/23391514","citation_count":117,"is_preprint":false},{"pmid":"15849733","id":"PMC_15849733","title":"Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15849733","citation_count":113,"is_preprint":false},{"pmid":"33357406","id":"PMC_33357406","title":"Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk.","date":"2020","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33357406","citation_count":111,"is_preprint":false},{"pmid":"24403070","id":"PMC_24403070","title":"Mlh1-Mlh3, a meiotic crossover and DNA mismatch repair factor, is a Msh2-Msh3-stimulated endonuclease.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24403070","citation_count":110,"is_preprint":false},{"pmid":"10778972","id":"PMC_10778972","title":"Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10778972","citation_count":103,"is_preprint":false},{"pmid":"19931261","id":"PMC_19931261","title":"An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19931261","citation_count":93,"is_preprint":false},{"pmid":"24981171","id":"PMC_24981171","title":"PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24981171","citation_count":89,"is_preprint":false},{"pmid":"14512394","id":"PMC_14512394","title":"Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer.","date":"2003","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14512394","citation_count":85,"is_preprint":false},{"pmid":"12435741","id":"PMC_12435741","title":"Transfer of the MSH2.MSH6 complex from proliferating cell nuclear antigen to mispaired bases in DNA.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12435741","citation_count":84,"is_preprint":false},{"pmid":"19436705","id":"PMC_19436705","title":"MSH2 ATPase domain mutation affects CTG*CAG repeat instability in transgenic mice.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19436705","citation_count":80,"is_preprint":false},{"pmid":"17636021","id":"PMC_17636021","title":"Saccharomyces cerevisiae Msh2-Msh3 acts in repair of base-base mispairs.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17636021","citation_count":80,"is_preprint":false},{"pmid":"12627520","id":"PMC_12627520","title":"Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.","date":"2003","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12627520","citation_count":79,"is_preprint":false},{"pmid":"12531017","id":"PMC_12531017","title":"Mutational specificity of mice defective in the MTH1 and/or the MSH2 genes.","date":"2002","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/12531017","citation_count":78,"is_preprint":false},{"pmid":"15713769","id":"PMC_15713769","title":"Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.","date":"2005","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/15713769","citation_count":76,"is_preprint":false},{"pmid":"9368761","id":"PMC_9368761","title":"Enhancement of MSH2-MSH3-mediated mismatch recognition by the yeast MLH1-PMS1 complex.","date":"1997","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9368761","citation_count":76,"is_preprint":false},{"pmid":"16341550","id":"PMC_16341550","title":"Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16341550","citation_count":75,"is_preprint":false},{"pmid":"12938096","id":"PMC_12938096","title":"Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12938096","citation_count":75,"is_preprint":false},{"pmid":"33874956","id":"PMC_33874956","title":"CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33874956","citation_count":65,"is_preprint":false},{"pmid":"11972333","id":"PMC_11972333","title":"Phosphorylation of mismatch repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-binding activity.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11972333","citation_count":62,"is_preprint":false},{"pmid":"10101166","id":"PMC_10101166","title":"Removal of one nonhomologous DNA end during gene conversion by a RAD1- and MSH2-independent pathway.","date":"1999","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10101166","citation_count":61,"is_preprint":false},{"pmid":"19267393","id":"PMC_19267393","title":"Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19267393","citation_count":56,"is_preprint":false},{"pmid":"9490293","id":"PMC_9490293","title":"Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility.","date":"1998","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9490293","citation_count":55,"is_preprint":false},{"pmid":"11830642","id":"PMC_11830642","title":"Caenorhabditis elegans DNA mismatch repair gene msh-2 is required for microsatellite stability and maintenance of genome integrity.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11830642","citation_count":54,"is_preprint":false},{"pmid":"16106253","id":"PMC_16106253","title":"The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16106253","citation_count":53,"is_preprint":false},{"pmid":"14706347","id":"PMC_14706347","title":"Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.","date":"2004","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/14706347","citation_count":52,"is_preprint":false},{"pmid":"12101417","id":"PMC_12101417","title":"Association of p53 and MSH2 with recombinative repair complexes during S phase.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12101417","citation_count":50,"is_preprint":false},{"pmid":"24966277","id":"PMC_24966277","title":"Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.","date":"2014","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/24966277","citation_count":49,"is_preprint":false},{"pmid":"19435918","id":"PMC_19435918","title":"Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19435918","citation_count":48,"is_preprint":false},{"pmid":"27546332","id":"PMC_27546332","title":"Crosstalk between MSH2-MSH3 and polβ promotes trinucleotide repeat expansion during base excision repair.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27546332","citation_count":48,"is_preprint":false},{"pmid":"8880570","id":"PMC_8880570","title":"Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome.","date":"1996","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8880570","citation_count":46,"is_preprint":false},{"pmid":"21093954","id":"PMC_21093954","title":"Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers.","date":"2010","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/21093954","citation_count":46,"is_preprint":false},{"pmid":"26097592","id":"PMC_26097592","title":"Relationship between MLH-1, MSH-2, PMS-2,MSH-6 expression and clinicopathological features in colorectal cancer.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26097592","citation_count":44,"is_preprint":false},{"pmid":"11879922","id":"PMC_11879922","title":"Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography.","date":"2002","source":"Journal of biochemical and biophysical methods","url":"https://pubmed.ncbi.nlm.nih.gov/11879922","citation_count":44,"is_preprint":false},{"pmid":"9600339","id":"PMC_9600339","title":"Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents.","date":"1998","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9600339","citation_count":44,"is_preprint":false},{"pmid":"17157869","id":"PMC_17157869","title":"Saccharomyces cerevisiae MSH2-MSH3 and MSH2-MSH6 complexes display distinct requirements for DNA binding domain I in mismatch recognition.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17157869","citation_count":43,"is_preprint":false},{"pmid":"21307385","id":"PMC_21307385","title":"Regulation of plant MSH2 and MSH6 genes in the UV-B-induced DNA damage response.","date":"2011","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/21307385","citation_count":42,"is_preprint":false},{"pmid":"21360204","id":"PMC_21360204","title":"Mutation deep within an intron of MSH2 causes Lynch syndrome.","date":"2011","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21360204","citation_count":42,"is_preprint":false},{"pmid":"30061603","id":"PMC_30061603","title":"Identification of Exo1-Msh2 interaction motifs in DNA mismatch repair and new Msh2-binding partners.","date":"2018","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30061603","citation_count":41,"is_preprint":false},{"pmid":"16331258","id":"PMC_16331258","title":"Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16331258","citation_count":41,"is_preprint":false},{"pmid":"12754350","id":"PMC_12754350","title":"p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme.","date":"2003","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12754350","citation_count":40,"is_preprint":false},{"pmid":"12684669","id":"PMC_12684669","title":"Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.","date":"2003","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12684669","citation_count":38,"is_preprint":false},{"pmid":"14735197","id":"PMC_14735197","title":"Germline truncating mutations in both MSH2 and BRCA2 in a single kindred.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14735197","citation_count":36,"is_preprint":false},{"pmid":"11604476","id":"PMC_11604476","title":"1,2-Dimethylhydrazine-induced colon carcinoma and lymphoma in msh2(-/-) mice.","date":"2001","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/11604476","citation_count":36,"is_preprint":false},{"pmid":"12222686","id":"PMC_12222686","title":"DNA binding properties of the yeast Msh2-Msh6 and Mlh1-Pms1 heterodimers.","date":"2002","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12222686","citation_count":34,"is_preprint":false},{"pmid":"17297472","id":"PMC_17297472","title":"Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17297472","citation_count":33,"is_preprint":false},{"pmid":"18986375","id":"PMC_18986375","title":"MSH2 deficiency abolishes the anticancer and pro-aging activity of short telomeres.","date":"2009","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/18986375","citation_count":32,"is_preprint":false},{"pmid":"19377479","id":"PMC_19377479","title":"The nucleotide binding dynamics of human MSH2-MSH3 are lesion dependent.","date":"2009","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19377479","citation_count":31,"is_preprint":false},{"pmid":"18381419","id":"PMC_18381419","title":"Origins and prevalence of the American Founder Mutation of MSH2.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18381419","citation_count":31,"is_preprint":false},{"pmid":"24400091","id":"PMC_24400091","title":"Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24400091","citation_count":31,"is_preprint":false},{"pmid":"22277660","id":"PMC_22277660","title":"Biochemical analysis of the human mismatch repair proteins hMutSα MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D).","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22277660","citation_count":30,"is_preprint":false},{"pmid":"24360395","id":"PMC_24360395","title":"Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung.","date":"2013","source":"Revista portuguesa de pneumologia","url":"https://pubmed.ncbi.nlm.nih.gov/24360395","citation_count":30,"is_preprint":false},{"pmid":"30397068","id":"PMC_30397068","title":"MSH2 Gene Point Mutations Are Not Antifungal Resistance Markers in Candida glabrata.","date":"2018","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/30397068","citation_count":29,"is_preprint":false},{"pmid":"12584560","id":"PMC_12584560","title":"Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12584560","citation_count":29,"is_preprint":false},{"pmid":"17039271","id":"PMC_17039271","title":"The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome.","date":"2007","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17039271","citation_count":29,"is_preprint":false},{"pmid":"33640455","id":"PMC_33640455","title":"OTUB1 stabilizes mismatch repair protein MSH2 by blocking ubiquitination.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33640455","citation_count":28,"is_preprint":false},{"pmid":"28591715","id":"PMC_28591715","title":"BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28591715","citation_count":28,"is_preprint":false},{"pmid":"24038355","id":"PMC_24038355","title":"Mismatch repair protein MSH2 regulates translesion DNA synthesis following exposure of cells to UV radiation.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24038355","citation_count":27,"is_preprint":false},{"pmid":"29342268","id":"PMC_29342268","title":"Reduced Expression of Mismatch Repair Genes MSH6/MSH2 Directly Promotes Pituitary Tumor Growth via the ATR-Chk1 Pathway.","date":"2018","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29342268","citation_count":27,"is_preprint":false},{"pmid":"25429050","id":"PMC_25429050","title":"Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.","date":"2014","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/25429050","citation_count":26,"is_preprint":false},{"pmid":"22285073","id":"PMC_22285073","title":"Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.","date":"2011","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/22285073","citation_count":25,"is_preprint":false},{"pmid":"15920474","id":"PMC_15920474","title":"Opposing roles for DNA structure-specific proteins Rad1, Msh2, Msh3, and Sgs1 in yeast gene targeting.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15920474","citation_count":24,"is_preprint":false},{"pmid":"20846263","id":"PMC_20846263","title":"Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma.","date":"2010","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/20846263","citation_count":24,"is_preprint":false},{"pmid":"7838728","id":"PMC_7838728","title":"Cloning and expression of the Xenopus and mouse Msh2 DNA mismatch repair genes.","date":"1994","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/7838728","citation_count":24,"is_preprint":false},{"pmid":"30149959","id":"PMC_30149959","title":"Expressional analysis of MLH1 and MSH2 in breast cancer.","date":"2018","source":"Current problems in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30149959","citation_count":23,"is_preprint":false},{"pmid":"8198129","id":"PMC_8198129","title":"Hereditary nonpolyposis colon cancer: analysis of linkage to 2p15-16 places the COCA1 locus telomeric to D2S123 and reveals genetic heterogeneity in seven Canadian families.","date":"1994","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8198129","citation_count":22,"is_preprint":false},{"pmid":"24995467","id":"PMC_24995467","title":"Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.","date":"2014","source":"Neurological research","url":"https://pubmed.ncbi.nlm.nih.gov/24995467","citation_count":22,"is_preprint":false},{"pmid":"23485110","id":"PMC_23485110","title":"Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth.","date":"2012","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/23485110","citation_count":22,"is_preprint":false},{"pmid":"37872134","id":"PMC_37872134","title":"MSH2 stimulates interfering and inhibits non-interfering crossovers in response to genetic polymorphism.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37872134","citation_count":21,"is_preprint":false},{"pmid":"12582944","id":"PMC_12582944","title":"Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme.","date":"2003","source":"Zentralblatt fur Neurochirurgie","url":"https://pubmed.ncbi.nlm.nih.gov/12582944","citation_count":21,"is_preprint":false},{"pmid":"31798786","id":"PMC_31798786","title":"Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer.","date":"2019","source":"World journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31798786","citation_count":21,"is_preprint":false},{"pmid":"11429706","id":"PMC_11429706","title":"Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11429706","citation_count":20,"is_preprint":false},{"pmid":"19486659","id":"PMC_19486659","title":"Conformational change in MSH2-MSH6 upon binding DNA coupled to ATPase activity.","date":"2009","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19486659","citation_count":20,"is_preprint":false},{"pmid":"15947132","id":"PMC_15947132","title":"MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15947132","citation_count":20,"is_preprint":false},{"pmid":"18781619","id":"PMC_18781619","title":"MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system.","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18781619","citation_count":19,"is_preprint":false},{"pmid":"30798936","id":"PMC_30798936","title":"Elucidating the role of interacting residues of the MSH2-MSH6 complex in DNA repair mechanism: A computational approach.","date":"2019","source":"Advances in protein chemistry and structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/30798936","citation_count":19,"is_preprint":false},{"pmid":"32154170","id":"PMC_32154170","title":"Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32154170","citation_count":18,"is_preprint":false},{"pmid":"17331550","id":"PMC_17331550","title":"The effects of MSH2 deficiency on spontaneous and radiation-induced mutation rates in the mouse germline.","date":"2007","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/17331550","citation_count":18,"is_preprint":false},{"pmid":"25503122","id":"PMC_25503122","title":"Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma.","date":"2014","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25503122","citation_count":17,"is_preprint":false},{"pmid":"28528517","id":"PMC_28528517","title":"Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.","date":"2017","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28528517","citation_count":16,"is_preprint":false},{"pmid":"12489114","id":"PMC_12489114","title":"Msh2 deficiency increases the mutation frequency in all parts of the mouse colon.","date":"2002","source":"Environmental and molecular mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12489114","citation_count":15,"is_preprint":false},{"pmid":"12584170","id":"PMC_12584170","title":"Msh2 deficiency enhances somatic Apc and p53 mutations in Apc+/-Msh2-/- mice.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12584170","citation_count":14,"is_preprint":false},{"pmid":"35583999","id":"PMC_35583999","title":"Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35583999","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51434,"output_tokens":7817,"usd":0.135778,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17397,"output_tokens":4873,"usd":0.104405,"stage2_stop_reason":"end_turn"},"total_usd":0.240183,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Human MSH2 (hMSH2) is a homolog of bacterial MutS and yeast MSH proteins. Expression of hMSH2 in E. coli causes a dominant mutator phenotype, consistent with interference with the normal bacterial mismatch repair pathway, establishing MSH2 as a mismatch repair factor.\",\n      \"method\": \"Heterologous expression in E. coli with mutator phenotype readout; gene mapping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional expression assay in bacteria replicated in subsequent studies; foundational paper establishing the basic function\",\n      \"pmids\": [\"8252616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Yeast MSH2, MLH1, and PMS1 form a ternary complex during mismatch repair initiation: MLH1 and PMS1 physically associate as a heterodimer and together bind an MSH2-heteroduplex complex containing a G-T mismatch.\",\n      \"method\": \"Physical interaction/co-binding assay; in vitro ternary complex formation with G-T mismatch-containing heteroduplex DNA\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of ternary complex, replicated by subsequent biochemical studies\",\n      \"pmids\": [\"8066446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"S. cerevisiae MSH2 operates via two mismatch repair pathways: one recognizing single-base mispairs requiring MSH2-MSH6, and a second recognizing insertion/deletion mispairs requiring MSH2-MSH3 or MSH2-MSH6. MSH2 physically interacts with both MSH3 and MSH6 to form distinct heterodimers.\",\n      \"method\": \"Mutation rate measurement across msh2/msh3/msh6 combinations; physical interaction studies between MSH2 and MSH3/MSH6\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis combined with physical interaction studies, replicated across multiple studies\",\n      \"pmids\": [\"8600025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Human MSH2 protein binds to slipped-strand DNA structures (S-DNA and SI-DNA) formed from trinucleotide repeat sequences (CTG/CAG) in a structure-specific and length-dependent manner, with preferential binding to looped-out CAG repeat sequences.\",\n      \"method\": \"Band-shift (EMSA) assay with purified MSH2 protein and synthetic slipped-strand DNA substrates\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro binding assay with purified protein, single lab, single method\",\n      \"pmids\": [\"9215683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The yeast MLH1-PMS1 heterodimer, by itself showing no affinity for mismatched DNA, greatly enhances the mismatch binding ability of MSH2-MSH3 upon interaction.\",\n      \"method\": \"Purification of MLH1-PMS1 heterodimer; gel mobility shift assay for mismatch DNA binding enhancement\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins, biochemical binding assay, single lab but orthogonal readouts\",\n      \"pmids\": [\"9368761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Msh2 is required for in vivo DNA damage-induced apoptosis in the intestinal epithelium in response to methylating agents (temozolomide, MNNG, cisplatin). This apoptotic response is primarily mediated through a p53-dependent pathway, with a secondary p53-independent delayed death also requiring Msh2.\",\n      \"method\": \"Msh2 null mouse model; in vivo apoptosis assay after genotoxic treatment; double-mutant analysis with p53\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse model with defined phenotypic readout, epistasis with p53, replicated in subsequent studies\",\n      \"pmids\": [\"10097137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MSH3 and MSH6, but not MSH2, contain N-terminal PCNA-interacting motifs. MSH2-MSH6 complex binds PCNA through MSH6's motif; alanine substitutions in the PCNA-binding motif of Msh6 or Msh3 elevated mutation rates. MSH3/MSH6 interaction with PCNA facilitates early steps in mismatch repair.\",\n      \"method\": \"Peptide binding to PCNA; alanine-substitution mutagenesis; mutation rate assay in yeast; mismatch repair inhibition assay in human cell extract\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with functional readout, peptide binding assay, in vitro repair inhibition assay; multiple orthogonal methods\",\n      \"pmids\": [\"11005803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MSH2-MSH6 (MutSα) forms a stable ternary complex with PCNA on homoduplex DNA, but MSH2-MSH6 binding to a heteroduplex (G/T mismatch) disrupts its interaction with PCNA. ATP addition restores PCNA binding, supporting a model where MSH2-MSH6 is transferred from PCNA to mispaired bases.\",\n      \"method\": \"Gel filtration and pull-down assays; ternary complex formation with PCNA, MSH2-MSH6, and homoduplex or heteroduplex DNA; ATP addition experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins, multiple conditions tested, mechanistic model supported by biochemical data\",\n      \"pmids\": [\"12435741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MSH2 and MSH6 are phosphorylated in vitro by protein kinase C and casein kinase II (but not PKA), and are phosphorylated in vivo. Phosphorylation of MSH2 and MSH6 increases mismatch-binding activity of MutSα and is required for methylation-induced nuclear translocation of the MutSα repair complex.\",\n      \"method\": \"In vitro kinase assays; phosphatase treatment and kinase inhibitor experiments in cells; mismatch-binding assay; subcellular localization by fractionation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo phosphorylation with functional consequence (binding and translocation), multiple methods, single lab\",\n      \"pmids\": [\"11972333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MSH2 and p53 co-localize in discrete nuclear foci during S phase, associate with recombination factors Rad50 and Rad51, and coexist in the same nuclear DNA-protein complexes during S phase, suggesting MSH2 plays a role in homologous recombination surveillance during DNA replication.\",\n      \"method\": \"Immunofluorescence colocalization; nuclear fractionation with co-immunoprecipitation; cell synchronization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and colocalization, multiple methods, single lab\",\n      \"pmids\": [\"12101417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MSH2 interacts with the ATR kinase to form a signaling module that regulates phosphorylation of Chk1 and SMC1 in response to the DNA methylating agent MNNG. MSH2 and Rad17 are required for S-phase checkpoint activation to suppress DNA synthesis after MNNG treatment.\",\n      \"method\": \"Co-immunoprecipitation of endogenous MSH2 and ATR; siRNA knockdown; checkpoint assays; Chk1 and SMC1 phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional epistasis (knockdown and checkpoint assay), multiple orthogonal methods in single lab\",\n      \"pmids\": [\"14657349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The DNA mismatch repair and DNA damage-induced apoptosis functions of Msh2 can be uncoupled: the G674A missense mutation in the conserved ATPase domain abrogates mismatch repair but retains DNA damage signaling for apoptosis. Msh2-mediated apoptosis is an independent tumor suppressor function.\",\n      \"method\": \"Knock-in mouse model (Msh2-G674A); tumor formation assay; chemotherapy response assay; apoptosis measurement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knock-in mouse with separation-of-function mutation, phenotypic readout across multiple cancer and drug-response endpoints; replicated in biochemical studies\",\n      \"pmids\": [\"14744764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERCC1 physically interacts with MSH2 complexes in HeLa cell extracts. The minimum region in ERCC1 required for co-immunoprecipitation of MSH2 is the carboxyl-terminal domain (aa 184-260), overlapping with the XPF-binding domain. This interaction is involved cooperatively in resistance to cisplatin (CDDP) in mammalian cells; MSH2 deficiency suppresses ERCC1-dependent CDDP resistance in XPA-deficient cells.\",\n      \"method\": \"Co-immunoprecipitation from HeLa cell extracts; tagged ERCC1 in COS7 cells; siRNA knockdown; double mutant cell analysis (Xpa/Msh2 null cells)\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus genetic epistasis in null cells, single lab, multiple methods\",\n      \"pmids\": [\"14706347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Human MSH2-MSH3 binds to CAG-hairpin DNA (an expansion intermediate); this binding inhibits the ATPase activity of MSH2-MSH3 and alters both ADP/ATP affinity and protein-DNA binding interfaces. Inhibition depends on A.A mispairs in the hairpin stem and the hairpin structure itself. This functional defect is proposed to misdirect repair and promote expansion.\",\n      \"method\": \"In vitro binding assay with purified MSH2-MSH3 and synthetic CAG-hairpin DNA; ATPase assay; nucleotide binding assay; mutagenesis of hairpin substrate\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — purified protein with synthetic substrates, multiple biochemical assays (binding, ATPase, nucleotide affinity), single lab\",\n      \"pmids\": [\"16025128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The MSH2 DNA-binding domain I (msh2Δ1 deletion) shows a separation-of-function phenotype: it is dispensable for MSH2-MSH6-mediated MMR but is required for MSH2-MSH3-mediated MMR. Domain I of MSH2 contributes a non-specific DNA binding activity, while domain I of MSH3 contributes mismatch binding specificity.\",\n      \"method\": \"Yeast genetic assays (mutation rate); purified Msh2-Msh3 mispair binding analysis; domain deletion mutants\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding with purified proteins plus genetic readout, multiple complementary methods, single lab\",\n      \"pmids\": [\"17157869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Msh2-Msh3 exhibits robust binding to specific base-base mispairs (not only insertion/deletion loops), consistent with a role in repair of base-base mismatches and suppression of homology-mediated duplication/deletion mutations; this parallels Mlh1-Mlh3 mutant phenotypes.\",\n      \"method\": \"Yeast genetic assays (mutation rate, mutation spectrum at CAN1); purified Msh2-Msh3 mispair binding assay with DNA substrates derived from CAN1\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding with purified protein plus genetic assays, orthogonal methods, single lab\",\n      \"pmids\": [\"17636021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MSH2-MSH3 recognizes small DNA loops via a mechanism distinct from MSH2-MSH6. Upon loop binding, MSH2-MSH3 adopts a specific nucleotide signature (ADP in MSH2, empty MSH3 subunit). ATP binding and hydrolysis in MSH3 promotes ADP-ATP exchange in MSH2, generating a hydrolysis-independent ATP-MSH2-MSH3-ADP intermediate specific to loop-bound complex.\",\n      \"method\": \"Nucleotide binding assays with purified human MSH2-MSH3; ATPase assays; fluorescence-based nucleotide occupancy measurements on defined DNA substrates\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assays with purified protein, multiple nucleotide binding methods, mechanistic detail established in single rigorous study\",\n      \"pmids\": [\"19377479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The MSH2 ATPase domain G674A mutation strongly reduces CTG repeat expansion and leads instead to contractions in DM1 transgenic mice (mimicking Msh2-null or Msh3-null deficiency), establishing that trinucleotide repeat expansion requires a functional MSH2 ATPase domain.\",\n      \"method\": \"Transgenic mouse cross; repeat instability analysis; protein level measurement\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean mouse genetic experiment with separation-of-function allele, quantitative repeat instability readout, single lab\",\n      \"pmids\": [\"19436705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MSH2 conformational change upon DNA binding is allosterically coupled to ATPase domain activity: in the absence of DNA, the clamp and lever domains of MSH6 and MSH2 open asymmetrically, and this opening is coupled to changes in the ATPase domains that diminish ATPase activity.\",\n      \"method\": \"Molecular dynamics simulation of human MSH2-MSH6 based on crystal structure; analysis of domain movements and ATPase domain changes\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational simulation only, no experimental validation in this paper\",\n      \"pmids\": [\"19486659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MSH2 deficiency in telomerase-deficient mice abolishes p21/p53-dependent cell-cycle arrest in response to short telomeres, eliminating the tumor suppressor activity of short telomeres and preventing degenerative pathologies by rescuing proliferative defects.\",\n      \"method\": \"Double knockout mice (MSH2(-/-) Terc(-/-)); tumor analysis; proliferation assay; p21/p53 pathway analysis\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double KO mouse model with defined phenotypic readouts, single lab\",\n      \"pmids\": [\"18986375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Human MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D) mutant proteins both fail to support mismatch repair in vitro while retaining mismatch recognition activity. MSH2(G674A)-MSH6 has a partial defect in nucleotide binding, while MSH2-MSH6(T1219D) fails to couple nucleotide binding and mismatch recognition. Both mutants remain bound at the mismatch and fail to promote excision, inhibiting MMR in a dominant manner.\",\n      \"method\": \"In vitro mismatch repair assay; kinetic DNA binding assays; ATPase activity measurement; excision step analysis with purified mutant proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified mutant proteins, multiple biochemical assays, mechanistic separation of defects established\",\n      \"pmids\": [\"22277660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HDAC6 sequentially deacetylates and ubiquitinates MSH2, leading to its proteasomal degradation. HDAC6 reduces cellular MSH2 levels, decreases mismatch repair activity, and reduces cellular sensitivity to DNA-damaging agents.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay; HDAC6 depletion/overexpression; mismatch repair activity assay; cell sensitivity assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional ubiquitination assays plus cellular readouts (MMR activity, drug sensitivity), multiple methods, single lab\",\n      \"pmids\": [\"24882211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Yeast Mlh1-Mlh3 is a metal-dependent endonuclease that is stimulated by Msh2-Msh3 to make single-strand breaks in supercoiled DNA, supporting a direct role for this endonuclease activity in resolving recombination intermediates and in mismatch repair.\",\n      \"method\": \"Purification of Mlh1-Mlh3; in vitro endonuclease assay; stimulation by purified Msh2-Msh3\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins, direct enzymatic activity assay, single lab\",\n      \"pmids\": [\"24403070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair. PCNA mutations disrupting Msh2-Msh6 binding or Mlh1-Pms1 endonuclease activation impair Exo1-independent MMR; Msh2-Msh6 localizes PCNA to repair sites after mispair recognition to activate the endonuclease.\",\n      \"method\": \"Genetic screen for PCNA mutants; mismatch repair assays; Mlh1-Pms1 focus accumulation assay; epistasis with msh6 PCNA-binding mutants\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic screen with multiple alleles plus epistasis plus cell biological assay (foci), replicated through multiple experimental approaches\",\n      \"pmids\": [\"24981171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Depletion of MSH2 suppresses aberrant DNA damage response and ICL sensitivity in cells lacking FANCJ-MLH1 interaction, BRCA1, or FANCD2, demonstrating that MSH2-dependent DNA damage signaling underlies synthetic lethality in BRCA-FA pathway-deficient cells. Rescue is through a Rad18-dependent mechanism.\",\n      \"method\": \"siRNA depletion of MSH2; cell viability and ICL sensitivity assays; cell cycle analysis; Msh2 null mouse cells (Fancd2-null primary cells); epistasis with Rad18\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in multiple cell backgrounds plus mouse cell validation, single lab\",\n      \"pmids\": [\"24966277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MSH2-MSH3 acts as a component of the BER machinery to promote trinucleotide repeat expansion: MSH2-MSH3 stimulates DNA polymerase β (pol β) to copy through TNRs and enhances formation of the flap precursor for expansion, converting the outcome of TNR instability from deletion to expansion during oxidized base removal.\",\n      \"method\": \"In vitro BER reconstitution assay with purified MSH2-MSH3 and pol β; flap formation assay; deletion/expansion measurement with defined DNA substrates\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins and defined substrates, multiple functional assays, single lab\",\n      \"pmids\": [\"27546332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The C-terminal unstructured domain of yeast Exo1 contains two Msh2-interacting peptide (SHIP) boxes that interact with Msh2 to recruit Exo1 to repair sites. The msh2-M470I mutation eliminates SHIP-Msh2 interactions. Wild-type but not mutant SHIP peptides block Exo1-dependent MMR in vitro, establishing that Msh2 has a peptide-binding interface for Exo1 tethering.\",\n      \"method\": \"Yeast genetics; in vitro mismatch repair assay; SHIP peptide competition; mutagenesis (msh2-M470I); identification of new SHIP-box proteins\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution plus mutagenesis and genetic validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30061603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MSH2 physically interacts with DNA polymerase kappa (Polκ). MSH2 depletion impairs PCNA monoubiquitination and the formation of UV-induced Polκ and other TLS polymerase foci. MSH2 can also regulate post-UV TLS polymerase focus formation in a PCNA monoubiquitination-independent fashion (in Rad18-deficient cells), facilitating translesion synthesis across CPD photoproducts.\",\n      \"method\": \"Co-immunoprecipitation combined with mass spectrometry; siRNA knockdown; focus formation assay after UV; TLS assay in living cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS identification plus functional readouts (focus formation, TLS), single lab, multiple methods\",\n      \"pmids\": [\"24038355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"OTUB1 (an OTU family deubiquitinase) inhibits MSH2 ubiquitination by blocking E2 ligase ubiquitin transfer activity. Depleting OTUB1 promotes ubiquitination and proteasomal degradation of MSH2, increases mutation frequency, and causes resistance to MNNG and cisplatin.\",\n      \"method\": \"Functional ubiquitination and deubiquitination assays; OTUB1 depletion in cells; mutation frequency assay; drug sensitivity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional ubiquitination assay plus cellular readouts (mutation rate, drug sensitivity), multiple methods, mechanistic model established, single lab\",\n      \"pmids\": [\"33640455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MAX, the heterodimeric partner of c-MYC, physically interacts with MSH2 both in vitro (GST pull-down) and in vivo (co-immunoprecipitation from tumor cell extracts), identifying MAX as a binding partner of MSH2.\",\n      \"method\": \"Yeast two-hybrid; GST-fusion pull-down; co-immunoprecipitation from human tumor cell extracts\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus in vitro pull-down, replicated in two experimental systems, single lab\",\n      \"pmids\": [\"12584560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MSH2 exerts a non-canonical epigenomic function in gastric cancer independent of its DNA repair catalytic activity: it binds tumor-associated super-enhancers controlling cell adhesion gene expression, enables chromatin rewiring and enhancer-promoter interactions, and maintains histone acetylation. This requires MSH6 and the SWI/SNF remodeler SMARCA4/BRG1. Loss of MSH2 causes deficient cell adhesion and synthetic lethality to BET inhibition.\",\n      \"method\": \"CRISPR-based mass spectrometry; genome-wide CRISPR functional screening; ChIP-seq; Hi-C (enhancer-promoter interaction); histone modification analysis; rescue experiments with catalytic-dead MSH2; in vitro and in vivo tumorigenesis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genomic and functional methods (CRISPR screen, ChIP, Hi-C, rescue with catalytic-dead mutant), multiple readouts establishing mechanistic independence from repair activity\",\n      \"pmids\": [\"35583999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Msh2 deficiency in primary mouse embryonic fibroblasts leads to chromosome aneuploidy, centrosome amplification, defective mitotic spindle organization, unequal chromosome segregation, and increased chromosome end-to-end fusions (telomere capping defects), without changes in telomerase activity, telomere length, or telomere recombination.\",\n      \"method\": \"Msh2(-/-) MEFs; cytogenetic analysis; centrosome immunofluorescence; telomere FISH; telomerase activity assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO cells with multiple cytological readouts (cytogenetics, centrosome, telomere), single lab\",\n      \"pmids\": [\"16331258\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MSH2 is an obligate subunit of the MutSα (MSH2-MSH6) and MutSβ (MSH2-MSH3) heterodimers that initiate eukaryotic DNA mismatch repair by recognizing base-base mismatches and insertion/deletion loops, respectively; upon mismatch binding, MSH2-MSH6 undergoes ATP-driven conformational changes that release it from PCNA (which loads the complex onto newly replicated DNA) and enable recruitment of the MLH1-PMS1/PMS2 endonuclease and Exo1 via direct MSH2-SHIP-box interactions; MSH2 also functions as a damage-signaling platform that interacts with ATR to phosphorylate Chk1 and SMC1 and trigger apoptosis independently of repair; MSH2-MSH3 additionally promotes trinucleotide repeat expansion by inhibiting ATPase activity when bound to CAG hairpins and by stimulating pol β during base excision repair; MSH2 protein stability is regulated by HDAC6-mediated deacetylation/ubiquitination (promoting degradation) and OTUB1-mediated deubiquitination (stabilization); and MSH2 has a non-canonical epigenomic role in which it binds super-enhancers via SMARCA4/BRG1 to maintain chromatin architecture at cell adhesion genes, independent of its catalytic repair activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MSH2 is the obligate, shared subunit of the eukaryotic mismatch-recognition heterodimers that initiate DNA mismatch repair (MMR): a MutS homolog whose heterologous expression confers a dominant mutator phenotype [#0], it partners with MSH6 to recognize base-base mispairs and with MSH3 to recognize insertion/deletion loops [#2], and these complexes nucleate a ternary repair assembly with the MLH1-PMS1 heterodimer at heteroduplex DNA [#1, #4]. Loading is coordinated with replication through PCNA, which forms a stable ternary complex with MutSα on homoduplex DNA; mismatch binding disrupts the PCNA interaction and ATP restores it, supporting transfer of MutSα from PCNA onto the mispair [#7], after which PCNA and MutSα activate the latent MLH1-PMS1 endonuclease and license Exo1-dependent or Exo1-independent excision [#23]; Exo1 is recruited directly through SHIP-box peptides that dock on an MSH2 interface disrupted by the msh2-M470I mutation [#26]. ATP-driven conformational cycling within the MSH2-MSH6 ATPase domains couples nucleotide binding to mismatch recognition and downstream excision, as defined by separation-of-function mutants (G674A and the MSH6 T1219D coupling mutant) that retain mismatch binding but fail to support repair [#20]. Beyond repair, MSH2 is a damage-signaling platform: it associates with ATR to drive Chk1 and SMC1 phosphorylation and S-phase checkpoint activation after methylation damage [#10] and is required for genotoxin-induced, largely p53-dependent apoptosis [#5]; this signaling function is genetically separable from repair, since the G674A ATPase mutant abolishes MMR yet preserves apoptotic tumor suppression [#11]. MSH2-MSH3 also promotes trinucleotide repeat expansion, binding CAG hairpins to inhibit its own ATPase [#13] and stimulating DNA polymerase β during base excision repair to convert repeat instability toward expansion [#25], a process requiring a functional MSH2 ATPase domain in vivo [#17]. MSH2 abundance is set by opposing enzymes—HDAC6-mediated deacetylation/ubiquitination promoting degradation [#21] and OTUB1-mediated protection from ubiquitination [#28]. Independent of catalytic repair, MSH2 carries a non-canonical epigenomic role, binding super-enhancers via MSH6 and SMARCA4/BRG1 to maintain chromatin architecture and cell adhesion gene expression [#30].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established MSH2 as the human counterpart of bacterial MutS and a bona fide mismatch repair factor, defining the gene's foundational function.\",\n      \"evidence\": \"Heterologous expression of hMSH2 in E. coli producing a dominant mutator phenotype, with gene mapping\",\n      \"pmids\": [\"8252616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which mammalian partners MSH2 uses\", \"No direct demonstration of mismatch binding by the human protein in this study\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved that MSH2 is a shared subunit forming two distinct heterodimers with division of substrate labor, explaining how a single protein covers both base-base and indel mispairs.\",\n      \"evidence\": \"Yeast mutation-rate epistasis across msh2/msh3/msh6 combinations plus MSH2-MSH3/MSH6 physical interaction assays\",\n      \"pmids\": [\"8600025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the structural basis of differential substrate recognition\", \"Human reconstitution not shown here\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Connected mismatch recognition to downstream MutL recruitment by showing MSH2-heteroduplex complexes form a ternary assembly with MLH1-PMS1 and that MLH1-PMS1 enhances MSH2-MSH3 mismatch binding.\",\n      \"evidence\": \"In vitro ternary complex formation on G-T heteroduplex DNA and gel-shift binding enhancement with purified MLH1-PMS1\",\n      \"pmids\": [\"8066446\", \"9368761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of events relative to replication not addressed\", \"Endonuclease activation step not yet defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Provided a biochemical basis for MSH2 involvement in trinucleotide repeat instability by showing structure-specific binding to slipped-strand repeat DNA.\",\n      \"evidence\": \"EMSA with purified MSH2 on synthetic CTG/CAG slipped-strand substrates\",\n      \"pmids\": [\"9215683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single method (EMSA)\", \"Functional consequence for expansion not tested here\", \"MSH2-MSH3 vs MSH2 alone not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the PCNA hand-off mechanism that times MutSα loading to replication, showing mismatch binding releases PCNA and ATP restores it.\",\n      \"evidence\": \"Gel filtration and pull-down ternary complex assays comparing homoduplex versus G/T heteroduplex with ATP addition\",\n      \"pmids\": [\"12435741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not show how released PCNA later activates the endonuclease\", \"In vivo timing not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linked MSH2 to broader S-phase genome surveillance by placing it in S-phase nuclear foci with p53 and recombination factors.\",\n      \"evidence\": \"Immunofluorescence colocalization and nuclear co-immunoprecipitation in synchronized cells\",\n      \"pmids\": [\"12101417\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative localization without direct functional dissection\", \"Whether MSH2 acts in homologous recombination not mechanistically shown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified MSH2 as a direct damage-signaling platform for the ATR-Chk1 axis, separating signaling from repair catalysis.\",\n      \"evidence\": \"Endogenous MSH2-ATR co-IP, siRNA knockdown, and Chk1/SMC1 phosphorylation and S-phase checkpoint assays after MNNG\",\n      \"pmids\": [\"14657349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase-substrate scaffolding mechanism not resolved\", \"Stoichiometry and dynamics of the MSH2-ATR module unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetically uncoupled MSH2's apoptotic/damage-signaling tumor suppressor role from its repair function using a separation-of-function ATPase mutant.\",\n      \"evidence\": \"Msh2-G674A knock-in mouse with tumor, chemotherapy-response, and apoptosis readouts\",\n      \"pmids\": [\"14744764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular reason the ATPase mutant retains signaling not defined\", \"Did not identify the signaling effector distinct from repair\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the biochemical mechanism for the repair/signaling split, showing ATPase and nucleotide-coupling mutants retain mismatch binding but stall before excision and act dominantly.\",\n      \"evidence\": \"In vitro MMR, kinetic DNA binding, ATPase, and excision assays with purified MSH2(G674A) and MSH6(T1219D) proteins\",\n      \"pmids\": [\"22277660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test apoptotic signaling output of these mutants biochemically\", \"Structural snapshot of the stalled intermediate not provided\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Completed the catalytic logic of initiation by showing PCNA plus MutSα activate the MLH1-PMS1 endonuclease for Exo1-independent repair.\",\n      \"evidence\": \"Yeast PCNA mutant screen with MMR assays, Mlh1-Pms1 focus accumulation, and epistasis with msh6 PCNA-binding mutants\",\n      \"pmids\": [\"24981171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of nick placement directionality not fully defined\", \"Human reconstitution not shown in this study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the direct molecular interface by which MSH2 tethers the nuclease Exo1 via SHIP-box peptides.\",\n      \"evidence\": \"Yeast genetics, in vitro MMR with SHIP peptide competition, and msh2-M470I interface mutagenesis\",\n      \"pmids\": [\"30061603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the SHIP-MSH2 interface not solved here\", \"Generality across other SHIP-box proteins only partially explored\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mechanistically explained how MSH2-MSH3 drives repeat expansion by acting within base excision repair to stimulate pol β and bias outcomes toward expansion.\",\n      \"evidence\": \"In vitro BER reconstitution with purified MSH2-MSH3 and pol β, flap-formation and deletion/expansion assays on defined substrates\",\n      \"pmids\": [\"27546332\", \"16025128\", \"19436705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo coordination between BER and MMR pathways at repeats not resolved\", \"Tissue-specific determinants of expansion not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that MSH2 protein levels, and thereby repair capacity and drug response, are set by opposing ubiquitin-pathway enzymes.\",\n      \"evidence\": \"HDAC6 deacetylation/ubiquitination and OTUB1 deubiquitination assays with cellular MMR activity, mutation frequency, and MNNG/cisplatin sensitivity readouts\",\n      \"pmids\": [\"24882211\", \"33640455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for MSH2 ubiquitination not pinpointed\", \"Crosstalk between acetylation and ubiquitination signals not fully mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a repair-independent epigenomic function in which MSH2 maintains super-enhancer chromatin architecture and cell adhesion gene expression.\",\n      \"evidence\": \"CRISPR-MS, genome-wide CRISPR screen, ChIP-seq, Hi-C, and rescue with catalytic-dead MSH2 in gastric cancer models\",\n      \"pmids\": [\"35583999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MSH2 is targeted to specific super-enhancers not fully defined\", \"Whether this role exists outside gastric cancer not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MSH2's repair, ATR-dependent signaling, repeat-expansion, and chromatin functions are partitioned and regulated within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking ATPase conformational states to the choice between repair, signaling, and chromatin roles\", \"The E3 ligase and full regulatory network controlling MSH2 stability are incomplete\", \"The recruitment determinants directing MSH2 to super-enhancers versus mismatches are unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 13, 14, 15, 16]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [7, 13, 16, 20]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [13, 16, 20]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [5, 10, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [23, 26]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 9, 10]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 2, 7, 23, 26]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [5, 10, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 11]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 17, 25]}\n    ],\n    \"complexes\": [\"MutSα (MSH2-MSH6)\", \"MutSβ (MSH2-MSH3)\"],\n    \"partners\": [\"MSH6\", \"MSH3\", \"MLH1\", \"PMS1\", \"PCNA\", \"EXO1\", \"ATR\", \"SMARCA4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}